Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736748 | 0.83 | CHRNB2 (0.53) | CHRNB2CHRNA4HRH4CHRNA1CHRNA7 | |
| SCHEMBL2422635 | 0.83 | EPHX2 (0.41) | KCNH2 | |
| SCHEMBL5466686 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4HRH4CHRNA1CHRNA7 | |
| SCHEMBL25328413 | 0.80 | HRH3 (0.39) | HRH4KCNH2 | |
| SCHEMBL12240380 | 0.80 | CHRNB2 (0.43) | CHRNB2CHRNA4HRH4ADRB1 | |
| SCHEMBL21262178 | 0.80 | KDM4E (0.51) | — | |
| SCHEMBL14335373 | 0.80 | HRH4 (0.47) | CHRNB2CHRNA4HRH4 | |
| SCHEMBL21262632 | 0.80 | SMN1; SMN2 (0.58) | HRH4 | |
| SCHEMBL902974 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4HRH4CHRNA1CHRNA7 | |
| Hydrochloric Acid SCHEMBL2379925 | 0.79 | CHRNB2 (0.42) | CHRNB2CHRNA4ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127333-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127333-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2621920-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| WO-2012044531-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044531-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, BAZ2A | CHRNB2 1589/4885CHRNA4 2068/4885HRH4 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.